deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02340676

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease

Sponsor: Dana-Farber Cancer Institute

Conditions Chronic Graft-versus-host-disease
Interventions Extracorporeal Photopheresis (ECP) Interleukin-2
Updated 24 times since 2017 Last updated: Feb 3, 2026 Started: Feb 28, 2015 Primary completion: Aug 31, 2017 Completion: Sep 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Graft-versus-host-disease, this trial is completed. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 24 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2022 · 13 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Feb 2024 · 10 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Oct 2025 · 7 months · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

24 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Oct 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 19 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Feb 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Jul 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Mar 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  13. Nov 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  14. Jul 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  15. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  16. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  17. Aug 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  18. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Prometheus Laboratories
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations